Feb. 13, 2025 -- The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL). LBCL is a fast-growing cancer of B ...

BMS’ Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.

A case study on how DelveInsight supported a client with a focused CAR-TCR Summit coverage plan to gain exclusive insights into CAR-T therapies for B-cell malignancies.New York, USA, Feb. 21, 2025 (GL ...

Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...

B-cells produce antibodies to attack bacteria ... There is some overlap in the definitions for some subtypes, such as T-lymphoblastic lymphoma/leukemia and adult T-cell lymphoma/leukemia.

reports the Daily Record. Fraser was diagnosed with lymphoblastic lymphoma, a form of blood cancer, and underwent months of rigorous treatment. The chemotherapy caused him to lose all his hair ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

The Scottish Medicines Consortium has backed NHS funding for Gilead’s CAR-T therapy Yescarta for B-cell lymphomas ... cleared for use in acute lymphoblastic lymphoma (ALL).

Stripping and reprobing the membrane with an antibody that recognized STAT5A and B showed differential STAT5 protein expression for each tumor (Figure 1c). To further demonstrate the presence and ...

The potential impact of this form of therapy in pediatric precursor B-lineage acute lymphoblastic leukemia ... tested in patients with non-Hodgkin's lymphoma (NHL), but not in patients with ...

SAN DIEGO — A bicistronic chimeric antigen receptor T-cell therapy induced durable response for most children with relapsed or refractory B-lineage acute lymphoblastic leukemia, findings ...

Pet owners can bring in their cats and dogs Saturday to Wizard of Paws for nail trims that will benefit a local girl battling ...